Welcome to our dedicated page for Dogwood Therapeutics SEC filings (Ticker: DWTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Dogwood Therapeutics filings document the regulatory record of a Delaware development-stage biopharmaceutical company focused on pain and neuropathy medicines. Its 8-K reports include financial results, Regulation FD shareholder letters, corporate updates, and material-event disclosures tied to the Halneuron® and SP16 IV development programs.
Proxy and meeting filings cover stockholder voting matters, governance, executive compensation, equity incentive plans, and Nasdaq-related approvals for warrant exercises and common stock issuances. The filing record also documents capital-structure matters, securities purchase agreements, equity awards, and risk-oriented disclosures associated with a clinical-stage biotechnology issuer.
Dogwood Therapeutics, Inc. is offering 2,338,948 shares of common stock at $2.85 per share in a takedown from its $150 million shelf registration, for gross proceeds of $6,666,002 and estimated net proceeds of approximately $6.0 million. The company plans to use the cash primarily to advance clinical development of its lead non-opioid pain candidate Halneuron® and for working capital and general corporate purposes.
In a concurrent private placement, Dogwood is issuing unregistered pre-funded warrants for up to 2,047,089 shares and unregistered warrants for up to 4,386,037 shares, both outside this prospectus. Management notes cash and cash equivalents of approximately $6.5 million as of December 31, 2025 and recurring operating losses that have led auditors to include a going concern explanatory paragraph, so this equity raise is intended to help support ongoing operations despite significant dilution risk to existing shareholders.
Dogwood Therapeutics, Inc. (DWTX) reported a major insider ownership change as CK Life Sciences–affiliated entities converted non-voting preferred stock into common shares. On November 21, 2025, each share of Series A and Series A-1 Non-Voting Convertible Preferred Stock automatically converted into 10,000 shares of common stock following stockholder approval of the conversion.
Sealbond Limited reported the conversion of preferred stock into 21,610,950 shares of common stock, with 21,822,333 common shares beneficially owned directly afterward. Conjoint Inc., another affiliate, reported the conversion of Series A-1 Preferred Stock into 2,842,638 common shares, held indirectly. CK Life Sciences Int'l., (Holdings) Inc. is listed as a director by deputization and 10% owner through its subsidiaries but disclaims beneficial ownership except for any pecuniary interest.
Dogwood Therapeutics, Inc. reported that stockholders approved several key proposals at a special meeting held on November 21, 2025. The Second Amended and Restated Equity Incentive Plan was approved, increasing the shares of common stock reserved under the prior plan by 2,781,665 shares to a total of 2,972,787 shares. Stockholders also approved the potential issuance of common stock upon conversion of the Company’s Series A, Series A-1, and Series A-2 Non-Voting Convertible Preferred Stock. Following approval of the Series A conversion, the Company’s business combination with Sealbond Limited under the Share Exchange Agreement dated October 7, 2024 is complete. A quorum was present, with 820,239 shares representing 35.76% of voting power as of the record date, and all matters received sufficient votes, including for Nasdaq Listing Rule 5635 purposes.
Dogwood Therapeutics (Nasdaq: DWTX) filed its Q3 2025 10‑Q, reporting a net loss of $15.7 million as R&D climbed, driven by $12.0 million of acquired in‑process R&D tied to a new SP16 license. For the nine months, net loss was $30.5 million, including a $6.1 million loss recognized on a related‑party debt conversion.
Cash was $10,126,710, with net cash used in operating activities of $11,981,464 for the nine months. Management states there is substantial doubt about the company’s ability to continue as a going concern beyond the first quarter of 2026 without additional financing.
During March 2025, the company raised approximately $4.25 million net in a registered direct offering and exchanged $19.9 million of related‑party loans and interest into Series A‑1 Non‑Voting Convertible Preferred Stock. On September 29, 2025, Dogwood licensed SP16 from Serpin, issuing equity valued at $12,030,667. As of November 5, 2025, 2,293,162 common shares were outstanding.
Dogwood Therapeutics (DWTX) furnished an update on its financial performance. On November 6, 2025, the company announced results for the third quarter ended September 30, 2025 via a press release attached as Exhibit 99.1. The information is expressly furnished, not filed under the Exchange Act, which means it is not subject to Section 18 liabilities and is not incorporated by reference into other filings.
Dogwood Therapeutics (DWTX) called a virtual special meeting to seek stockholder approval to issue common stock upon conversion of three preferred series tied to recent transactions. Proposal 1 covers Series A, which would convert into 22,691,494 shares; Proposal 2 covers Series A-1 for 2,842,638 shares; Proposal 3 covers Series A-2 for 1,900,572 shares, each effective after approval and Nasdaq’s initial listing application.
The company reports 2,293,162 shares outstanding as of the record date. Following approval and conversion, it expects to issue 27,434,704 shares, for an expected total of 29,727,866 shares outstanding. Post-conversion, beneficial ownership is shown as Sealbond Limited 73.4% and Conjoint, Inc. 9.6%. Certain holders are excluded from voting on Proposals 1 and 3 under Nasdaq rules.
Proposal 4 seeks to increase the equity plan reserve to 2,972,787 shares. Proposal 5 would permit adjournment if needed to secure approvals or Nasdaq’s initial listing application. The meeting is on November 21, 2025 at 10:00 a.m. ET, with an October 14, 2025 record date.
Dogwood Therapeutics, Inc. filed an S-3/A registering the resale of up to 28,038,689 shares of Common Stock that may be sold from time to time by named selling stockholders. The company is not selling any shares and will not receive proceeds from these resales.
The registered shares include stock issued in prior transactions and shares underlying Series A, A-1 and A-2 non-voting convertible preferred stock, each convertible into 10,000 common shares upon required stockholder approvals. The filing notes that conversion of each preferred series requires stockholder approval. As of October 16, 2025, shares outstanding were 2,293,162. The prospectus states this offering itself will not increase outstanding shares unless conversions occur.
Holders may sell at their discretion under the plan of distribution. Examples include Sealbond Limited 21,822,333 and Conjoint Inc. 2,842,638. The company remains an emerging growth and smaller reporting company, with Common Stock listed on Nasdaq as “DWTX.”
Dogwood Therapeutics, Inc. filed a current report to let the market know it has posted an investor presentation on its website. The presentation, dated October 9, 2025, may be used in discussions with investors, analysts, collaborators, vendors and other third parties.
The presentation is furnished as Exhibit 99.1 to the report and is provided under a disclosure category that is not treated as formally filed with the SEC. This means it is available for information purposes but is not automatically incorporated into Dogwood’s Securities Act filings.
Dogwood Therapeutics, Inc. is presenting a preliminary proxy for a Special Meeting to approve several Nasdaq-related matters tied to newly issued preferred stock and equity plan changes. The filing notes that a 1.7 inhibitor has received FDA fast-track designation for chemotherapy-induced neuropathic pain, and states that an increase in capitalization backed by experienced investors will support research, partnerships and business development. The company issued 211,951 shares in connection with a Share Exchange Agreement and 382,034 shares under an Exclusive License Agreement; those shares are not entitled to vote on related proposals under Nasdaq rules. The Proposals seek shareholder approval for potential conversion issuances of Series A, A-1 and A-2 Non-Voting Convertible Preferred Stock, adoption of a revised 2020 Equity Incentive Plan, and authority to adjourn if additional proxy solicitation or Nasdaq approval is needed. The filing describes conversion mechanics, cash settlement rights for undelivered shares, voting limitations for street-held shares, abstention consequences (notably for Proposal No. 3) and timing windows for director nominations.
Dogwood Therapeutics, Inc. has filed a shelf registration on Form S-3 to register resale of shares under a prospectus that covers Common Stock and multiple series of Preferred Stock. The prospectus states 43,000,000 shares of Common Stock and 2,000,000 shares of preferred stock authorized, including specific Series allocations for Series A, A-1 and A-2. The document identifies named selling stockholders and discloses that percentages are based on 2,293,162 shares of Common Stock outstanding as of September 30, 2025. The prospectus incorporates recent SEC filings by reference, including the 2024 Form 10-K and multiple 10-Qs and 8-Ks filed in 2025, and includes customary undertakings regarding post-effective amendments, prospectus use and liability. The registration statement lists exhibits such as Certificates of Designation for the preferred series, legal opinions, accountant consents and powers of attorney and is signed by the CEO, CFO and members of the board.